Sadra Medical

The company's core business was the development and eventual commercialization of therapies for aortic valve disease, a condition that involves the thickening and stiffening of the heart's aortic valve, primarily affecting individuals over 65. Sadra Medical operated in the structural heart market, specifically targeting the percutaneous aortic valve replacement sector. Its business model was centered on research and development, funded by venture capital, with the goal of an acquisition by a major medical device corporation. The company successfully raised significant capital, including a $30 million Series C round in 2009, from a syndicate of investors including Accuitive Medical Ventures, Boston Scientific, Finistere, and SV Life Sciences.

Sadra Medical's principal product was the Lotus™ Valve System. This system consisted of a stent-mounted tissue valve prosthesis and a catheter delivery system designed for percutaneous aortic valve replacement. A key feature of the Lotus system was that it was the first fully repositionable and retrievable device for this procedure. This capability allowed physicians to accurately position, adjust, or even retrieve the valve at any point before final deployment, addressing a significant limitation of first-generation devices and aiming to improve clinical outcomes by ensuring precise placement. In November 2010, Boston Scientific announced a definitive agreement to acquire Sadra Medical, a transaction that was completed in January 2011. The deal involved an upfront payment of $193 million for the remaining equity, with potential for an additional $193 million in milestone-based payments, valuing the total deal at up to approximately $450 million.